Bishal Bhandari, DO
Interventional Cardiology · Colorado Springs, CONPI 1689104002
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (55.2%), food and beverage and grants — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Medtronic at 46.6% of the total. 2025 is the largest year on record at $4,127, more than ten times the $315 reported in 2021.
Across 88 payments — averaging $141.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$6K
- Abbott$2K
- Boston Scientific$2K
- Abiomed$842
- AstraZeneca$687
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$391
- plus $542 from 5 others
What the payments were for
- Grants$1,39811%
- Travel & lodging$6,85455%
- Food & beverage$4,15834%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 50 | $5,784 |
| Abbott | 12 | $2,461 |
| Boston Scientific | 4 | $1,702 |
| Abiomed | 3 | $842 |
| AstraZeneca | 9 | $687 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $391 |
| Acist Medical Systems, Inc. | 2 | $269 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $123 |
| Chiesi USA, Inc. | 1 | $72 |
| Penumbra, Inc. | 1 | $48 |
| Edwards Lifesciences | 1 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ONYX FRONTIER$2,007
- RESOLUTE ONYX$1,969
- XIENCE SKYPOINT$1,854
- Impella$771
- SYMPLICITY G3$364
- AMPLATZER$167
- RXI SYSTEMS$141
- CVI SYSTEMS$128
- LifeVest$126
- FARXIGA$124
- ARCALYST$123
- OPTIS$112
- AVVIGO Guidance System$104
How this compares
$12,410 in reported general payments places this provider in the 60th percentile of 111 interventional cardiology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 11 | $18,444 |
| Repatha SureclickEvolocumab | 14 | $8,260 |
| Metoprolol Succinate | 17 | $434 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 11 | $201 |
| Furosemide | 30 | $184 |
| Metoprolol Tartrate | 19 | $127 |
| Lisinopril | 12 | $85 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Colorado Springs
- Cihan CevikColorado Springs$64K
- Joseph LeeColorado Springs$15K
- Harshal PatilColorado Springs$9K
- Christopher KovachColorado Springs$8K
- Ehrin ArmstrongEnglewood$718K
- Gareth MorganAurora$536K
- Jamaluddin MolooAurora$272K
- Jenny Zablah AlabiAurora$269K
- Srinivas IyengarBoulder$254K
- Nima AghiliLakewood$220K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.